Novartis Restructures Swiss Operations with 550 Job Cuts While Investing $80M in RNA Therapy Production
核心洞察
Novartis plans to eliminate 550 positions at its Swiss Stein facility by 2027 as part of discontinuing production of tablets, capsules, and sterile medicine packaging.
The company will simultaneously invest $80 million in its Schweizerhalle facility to expand siRNA production capabilities, creating 80 new positions by 2028.
These strategic changes aim to maintain competitive manufacturing in Switzerland while focusing on innovative RNA therapies for cardiovascular, renal, and metabolic diseases (搜索).
Novartis announced plans to cut 550 positions at its Swiss Stein facility by the end of 2027 while simultaneously investing $80 million to expand RNA therapy production at its nearby Schweizerhalle site, creating 80 new jobs by 2028. The restructuring reflects the pharmaceutical giant's strategic shift toward innovative therapies and manufacturing optimization.
Production Changes at Stein Facility
The job cuts at Novartis' Stein site will accompany the discontinuation of several manufacturing activities, including production of solid oral dosage forms such as tablets and capsules, as well as sterile medicinal product packaging. However, the facility will maintain its commercial production of personalized cell therapies and sterile dosage form operations, which will receive a $26 million investment enhancement.
"We continue to invest in Switzerland, and our sites here still produce for over 120 countries," said Steffen Lang, president of operations at Novartis, emphasizing the company's ongoing commitment to Swiss manufacturing despite the workforce reduction.
Strategic Investment in RNA Therapeutics
The $80 million investment at Schweizerhalle will focus on expanding innovative siRNA production capabilities, positioning the facility as a key component of Novartis' therapeutic strategy in cardiovascular, renal, and metabolic diseases (搜索). This investment represents part of the company's broader effort to maintain competitive production in Switzerland through automation and innovative technologies.
Lang noted that Novartis is "investing in innovative technologies such as automation" to maintain competitive production in Switzerland. The total investment across Swiss production sites exceeds $100 million, demonstrating the company's commitment to modernizing its European operations.
Parallel US Expansion Continues
The Swiss restructuring operates independently of Novartis' major US manufacturing expansion. The company recently announced new facilities in North Carolina as part of a five-year, $23 billion commitment to increase its American manufacturing presence. The North Carolina expansion will create a "flagship hub" featuring end-to-end capabilities, including two new facilities prioritizing biologics production and sterile packaging.
"This announcement is a commitment to American innovation and to the patients we serve," said CEO Vas Narasimhan. "By building a full, end-to-end manufacturing presence in North Carolina for our broader portfolio, we are expanding our capacity to deliver medical breakthroughs, securing a more resilient US supply chain, and investing in the local communities that make our mission possible."
Broader Workforce Adjustments
The Swiss job cuts follow earlier workforce reductions in the United States, where Novartis announced plans in March to reduce its workforce by 427 positions at its New Jersey headquarters, with an additional 60 employees affected later in the year according to Worker Adjustment and Retraining Notification filings.
The company has also expanded its radioligand therapy manufacturing capabilities, opening its third facility for these treatments in California this month, complementing existing facilities in Florida and Texas. These moves reflect Novartis' strategic focus on specialized therapeutic areas and advanced manufacturing technologies while optimizing its global production footprint.